Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
Journal of Clinical Oncology2011Vol. 30(2), pp. 134–141
Citations Over TimeTop 1% of 2011 papers
Samuel A. Wells, Bruce G. Robinson, Robert F. Gagel, Henning Dralle, James A. Fagin, Massimo Santoro, Éric Baudin, Rossella Elisei, Barbara Jarząb, James R. Vasselli, Jessica Read, Peter Langmuir, Anderson J. Ryan, Martin Schlumberger
Abstract
Vandetanib demonstrated therapeutic efficacy in a phase III trial of patients with advanced MTC (ClinicalTrials.gov NCT00410761).
Related Papers
- → Libretto-531: A Phase III Study of Selpercatinib in Multikinase Inhibitor-Naïve RET -Mutant Medullary Thyroid Cancer(2022)30 cited
- → Progress in Molecular Targeted Therapy for Thyroid Cancer: Vandetanib in Medullary Thyroid Cancer(2011)24 cited
- → Vandetanib: A Guide to Its Use in Advanced Medullary Thyroid Cancer(2012)1 cited
- Experience with vandeta nib in medullary thyroid cancer(2014)
- → Analysis of treatment outcomes in patients with progressive locally advanced non-resectable and disseminated medullary thyroid cancer receiving vandetanib outside of clinical trials (Russian experience)(2020)